1. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-1285.
3. Valeyrie-Allanore L, Sassolas B, Roujeau JC. Drug-induced skin, nail and hair disorders. Drug Saf 2007;30:1011-1030.
4. Grover S. Severe cutaneous adverse reactions. Indian J Dermatol Venereol Leprol 2011;77:3-6.
6. Shin KS, Cho KH, Lee YS. Clinical study of hospitalized patients with drug eruption during a 10-year period (1976- 1985). Korean J Dermatol 1987;25:176-182.
7. Bang DS, Cho CK, Lee SN. A statistical study of dermatoses during the last 5 years (1976-1980). Korean J Dermatol 1983;21:37-44.
8. Lyu SM, Byun JY, Choi YW, Choi HY. Clinical features of dermatology-consulted inpatients: focus on the differences between individual departments. Korean J Dermatol 2014;52:215-221.
9. Lee MY, Byun JY, Choi HY, Choi YW. Clinical analysis of drug eruptions among inpatients seeking a consultation with the department of dermatology. Korean J Dermatol 2018;56:314-321.
10. Choi YW. Drug eruption. Ewha Med J 2012;35:76-82.
12. Barbaud A, Reichert-Penetrat S, Tréchot P, et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol 1998;139:49-58.
13. Goutham S, Rajendran N. Patterns of cutaneous drug reactions: a review. J Basic Clin Appl Health Sci 2019;2:134-137.
15. Chatterjee S, Ghosh AP, Barbhuiya J, Dey SK. Adverse cutaneous drug reactions: a one year survey at a dermatology outpatient clinic of a tertiary care hospital. Indian J Pharmacol 2006;38:429-431.
16. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions: a report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986;256:3358-3363.
17. Kim KY, Kim KJ, Kang HJ. Clinical study and skin tests of patients with drug eruptions. Korean J Dermatol 1993;31:681-690.
18. Kim KJ, Jeong MC, Yoo JH. Clinical study and skin tests of patients with drug eruptions. Korean J Dermatol 1998;36:887-896.
19. Chang KY, Park HJ, Lim YS, Choi HY, Myung KB. Clinical study and skin tests of patients with drug eruptions. Korean J Dermatol 1998;36:997-1004.
21. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol 2001;137:765-770.
22. Anderson JA, Adkinson NF. Allergic reactions to drugs and biologic agents. JAMA 1987;258:2891-2899.
23. Nigen S, Knowles SR, Shear NH. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol 2003;2:278-299.
24. Häusermann P, Harr T, Bircher AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome?. Contact Dermatitis 2004;51:297-310.
25. Josephs SH, Rothman SJ, Buckley RH. Phenytoin hypersensitivity. J Allergy Clin Immunol 1980;66:166-172.
26. Heelan K, Sibbald C, Shear NH. Cutaneous reactions to drugs. In: Kang SW, Amagai M, Bruckner AL, et al, Fitzpatrick’s dermatology. 9th ed. McGraw-Hill; 2019. p. 749-764.
27. Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol 2009;9:316-321.
28. Mizukawa Y, Yamazaki Y, Shiohara T. In vivo dynamics of intraepidermal CD8+ T cells and CD4+ T cells during the evolution of fixed drug eruption. Br J Dermatol 2008;158:1230-1238.
29. Tan EK, Grattan CE. Drug-induced urticaria. Expert Opin Drug Saf 2004;3:471-484.
30. Chung WH, Wang CW, Dao RL. Severe cutaneous adverse drug reactions. J Dermatol 2016;43:758-766.
31. Rzany B, Correia O, Kelly JP, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study: study group of the international case control study on severe cutaneous adverse reactions. Lancet 1999;353:2190-2194.
32. La Grenade L, Lee L, Weaver J, et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf 2005;28:917-924.
33. Aguiar D, Pazo R, Durán I, et al. Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider. J Neurooncol 2004;66:345-350.
34. Aydin F, Cokluk C, Senturk N, et al. Stevens-Johnson syndrome in two patients treated with cranial irradiation and phenytoin. J Eur Acad Dermatol Venereol 2006;20:588-590.
37. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-153.
39. Yip LW, Thong BY, Lim J, et al. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy 2007;62:527-531.
40. Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol 2007;157:989-996.
41. Ofuji S, Yamamoto O. Acute generalized exanthematous pustulosis associated with a human parvovirus B19 infection. J Dermatol 2007;34:121-123.
42. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996;15:250-257.
43. Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet 2017;390:1996-2011.
44. Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 2014;71:787-794.
45. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500.
46. Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008;158:592-596.
47. Habre M, Habre SB, Kourie HR. Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know. Immunotherapy 2016;8:1437-1446.
48. Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 2016;152:45-51.
49. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16:1425-1433.
50. Pérez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?. Oncology (Williston Park) 2003;17(11 Suppl 12):23-28.